ReviewFrontiers in immunology2019
Harnessing Dendritic Cells for Poly (D,L-lactide-
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 63 citations in OpenAlex.
- Recent advances in PLGA polymer nanocarriers for ovarian cancer therapy.Frontiers in oncology · 2025Review
- Engineering dendritic cell biomimetic membrane as a delivery system for tumor targeted therapy.Journal of nanobiotechnology · 2024Review
- Application of PLGA in Tumor Immunotherapy.Polymers · 2024Review
- Immune Potentiation of PLGA Controlled-Release Vaccines for Improved Immunological Outcomes.ACS omega · 2024Article
- Intradermal Vaccination with PLGA Nanoparticles via Dissolving Microneedles and Classical Injection Needles.Pharmaceutical research · 2024Article
- Potential of DPD ((S)-4,5-dihydroxy-2,3-pentanedione) Analogs in Microparticulate Formulation as Vaccine Adjuvants.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Tumor Antigen-Tethered Spiked Virus-Like- Poly(Lactic-Co-Glycolic Acid)-Nanoparticle Vaccine Enhances Antitumor Ability Through Th9 Promotion in Mice.International journal of nanomedicine · 2024Article
- Machine Learning for Predicting Drug Release Behavior of PLGA Microspheres.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2024Article
- Review
- Sec22b and Stx4 Depletion Has No Major Effect on Cross-Presentation of PLGA Microsphere-Encapsulated Antigen and a Synthetic Long Peptide In Vitro.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Novel Approaches to the Establishment of Local Microenvironment from Resorbable Biomaterials in the Brain In Vitro Models.International journal of molecular sciences · 2023Review
- Thiol-Michael Addition Microparticles: Their Synthesis, Characterization, and Uptake by Macrophages.ACS biomaterials science & engineering · 2023Article
- Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Vaccine-Induced Immunity Elicited by Microneedle Delivery of Influenza Ectodomain Matrix Protein 2 Virus-like Particle (M2e VLP)-Loaded PLGA Nanoparticles.International journal of molecular sciences · 2023Article
- Nanomaterials in tumor immunotherapy: new strategies and challenges.Molecular cancer · 2023Review
- Live Cell Imaging by Förster Resonance Energy Transfer Fluorescence to Study Trafficking of PLGA Nanoparticles and the Release of a Loaded Peptide in Dendritic Cells.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Article
- Properties of Poly (Lactic-co-Glycolic Acid) and Progress of Poly (Lactic-co-Glycolic Acid)-Based Biodegradable Materials in Biomedical Research.Pharmaceuticals (Basel, Switzerland) · 2023Review
- PLGA-Based Micro/Nanoparticles: An Overview of Their Applications in Respiratory Diseases.International journal of molecular sciences · 2023Review
- PLGA Particles in Immunotherapy.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With emerging success in fighting off cancer, chronic infections, and autoimmune diseases, immunotherapy has become a promising therapeutic approach compared to conventional therapies such as surgery, chemotherapy, radiation therapy, or immunosuppressive medication. Despite the advancement of monoclonal antibody therapy against immune checkpoints, the development of safe and efficient cancer vaccine formulations still remains a pressing medical need. Anti-tumor immunotherapy requires the induction of antigen-specific CD8+ cytotoxic T lymphocyte (CTL) responses which recognize and specifically destroy tumor cells. Due to the crucial role of dendritic cells (DCs) in initiating anti-tumor immunity, targeting tumor antigens to DCs has become auspicious in modern vaccine research. Over the last two decades, micron- or nanometer-sized particulate delivery systems encapsulating tumor antigens and immunostimulatory molecules into biodegradable polymers have shown great promise for the induction of potent, specific and long-lasting anti-tumor responses
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.